Use and composition for treating myasthenia gravis and other myasthenic syndromes
AssigneeDAS-MG, Inc.
InventorKathleen E. Clarence-Smith
Life of this patent
Estimating the term…
Abstract
The present invention provides a new compositions and methods to enable the safe administration of pyridostigmine to mammalian subjects, including those with myasthenic syndromes including Myasthenia Gravis, with said compositions comprising combinations, including fixed-dose combinations, of an antagonist of the 5-hydroxytryptamine subtype-3 receptor (“5HT3-antagonist”) with an effective dose of pyridostigmine. The compositions and methods of the present invention provide for an increase in the tolerable dose of pyridostigmine over that of pyridostigmine when administered alone.
Claims5
A fixed-dose combination product for administration to a mammal comprising a pharmaceutical composition in dosage unit form comprising as active ingredients (a) between 2 mg and 16 mg of a 5HT3-antagonist and (b) between 15 mg and 800 mg of pyridostigmine, which are (c) in admixture with a pharmaceutically acceptable carrier or vehicle.
Dependencies are inferred from the claim text.